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Abstract
Chemokines and their receptors are essential in the recruitment
and positioning of lymphocytes. To address the question of B
cell migration into the inflamed synovial tissue of patients with
rheumatoid arthritis (RA), peripheral blood naive B cells, memory
B cells and plasma cells were analyzed for cell surface
expression of the chemokine receptors CXCR3, CXCR4,
CXCR5, CCR5, CCR6, CCR7 and CCR9. For comparison, B
cells in the peripheral blood of patients with the autoimmune
disease systemic lupus erythematosus (SLE) or with the
degenerative disease osteoarthritis (OA) were analyzed.
Expression levels of chemokine receptors were measured by
flow cytometry and were compared between the different
patient groups and healthy individuals. The analysis of
chemokine receptor expression showed that the majority of
peripheral blood B cells is positive for CXCR3, CXCR4,
CXCR5, CCR6 and CCR7. Whereas a small fraction of B cells
were positive for CCR5, practically no expression of CCR9 was
found. In comparison with healthy individuals, in patients with RA
a significant fraction of B cells showed a decreased expression
of CXCR5 and CCR6 and increased levels of CXCR3. The
downregulation of CXCR5 correlated with an upregulation of
CXCR3. In patients with SLE, significant changes in CXCR5
expression were seen. The functionality of the chemokine
receptors CXCR3 and CXCR4 was demonstrated by
transmigration assays with the chemokines CXCL10 and
CXCL12, respectively. Our results suggest that chronic
inflammation leads to modulation of chemokine receptor
expression on peripheral blood B cells. However, differences
between patients with RA and patients with SLE point toward a
disease-specific regulation of receptor expression. These
differences may influence the migrational behavior of B cells.
Introduction
Rheumatoid arthritis (RA) is a complex autoimmune disease of
unknown etiology. It is characterized by chronic inflammation
of the synovial membrane and the formation of a pannus,
which leads to swollen joints and finally to joint destruction.
Inflammatory cells such as monocytes and neutrophils,
together with T and B cells, infiltrate the synovial membrane
[1]. Migration of lymphocytes from the blood to the synovial tis-
sue is a multi-step process controlled in part by interactions
between chemokines and their receptors [2,3].
About 50 chemokines have been identified in humans and are
divided into four groups according to their cysteine motifs [4].
After activation and differentiation, cells of the lymphoid line-
ages dynamically change their expression profiles of chemok-
ine receptors, which results in specific migration in response
to chemokines [5,6].
Under pathological conditions, such as RA, chemokines direct
lymphocytes into the chronically inflamed synovial tissue [7,8].
Both the residual synovial-lining cells and infiltrating leuko-
cytes are the source of pro-inflammatory chemokines such as
CCL2, CCL3, CCL5, CCL20, CXCL9 and CXCL10, as wellR1001
BSA = bovine serum albumin; ELISA = enzyme-linked immunosorbent assay; FITC = fluorescein isothiocyanate; FACS = fluorescence-activated cell 
sorting, mAb = monoclonal antibody; OA = osteoarthritis; PBMC = peripheral blood mononuclear cells; PE = phycoerythrin; RA = rheumatoid arthri-
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R1002as chemokines important for the homeostasis of lymphocytes,
such as CXCL12 and CXCL13 [2,9-13]. As a consequence
of the synovial inflammation, these chemokines are also found
in the synovial fluid.
Contradictory results have been reported for chemokine
receptor expression on peripheral blood T cells of patients
with RA [13,14] and even less is known about the expression
of chemokine receptors on B cells. The classical chemokine
receptor on B cells is CXCR5. Its ligand CXCL13 is a potent
B cell chemo-attractant molecule directing B cells into the fol-
licles of secondary lymphoid organs [15]. In addition to
CXCR5, the chemokine receptors CXCR4 and CCR7 have
been implicated in B cell migration into the follicular structures,
and especially CXCR4 in directing plasma cells into the bone
marrow [6]. These chemokines and their corresponding chem-
okine receptors are also expressed in the inflamed synovial tis-
sue of patients with RA. In particular, high expression of
CXCL13 was found when the synovial tissue contained large
aggregates of B cells, resembling the structure of germinal
centers [11,17]. These findings suggested that the chemokine
CXCL13 is involved in B cell trafficking into the inflamed tissue
and has a role in the formation of ectopic lymphoid tissue
[18,19].
CXCR3 is a chemokine receptor for the inflammatory chemok-
ines CXCL9, CXCL10 and CXCL11. It has been described as
a marker for malignant B cells and is absent from the majority
of normal peripheral blood B cells [20,21]. The analysis of
patients with multiple sclerosis showed that CXCR3 becomes
upregulated on infiltration of the inflamed cerebrospinal fluid
[20].
To address the question of B cell migration, we analyzed
chemokine receptor expression on peripheral blood B cells.
Expression profiles of patients with RA were compared with
those from patients with systemic lupus erythematosus (SLE),
who – in contrast to patients with RA – usually show no or very
little B cell accumulation at the site of chronic inflammation
[22]. In addition, patients with osteoarthritis (OA) were
included into the study as a control cohort. OA is a non-inflam-
matory degenerative joint disease. Our data suggest that the
chronic inflammation in patients with RA and patients with SLE
leads to changes in the chemokine receptor expression pat-
tern on peripheral B cells; however, the expression patterns of
chemokine receptors in RA and SLE are differentially
regulated.
Methods
Patients and controls
Heparinized whole blood (9 ml) from patients with RA, patients
with SLE and patients with OA was obtained from the Depart-
ments of Rheumatology and Orthopedics (Charité, Humboldt
University, Berlin, Germany). Patients with RA were diagnosed
in accordance with the American College of Rheumatology
criteria [23]. As control, blood samples from healthy blood
donors were analyzed. The demographic data and the treat-
ment of patients are summarized in Table 1. The scientific eth-
ics committee of Charité approved the study, and informed
consent was obtained.
Cell isolation and flow cytometry
Peripheral blood mononuclear cells (PBMC) were isolated by
gradient centrifugation with Ficoll (Amersham Biosciences)
and then stained (30 min at 4°C) with a biotin-coupled B cell-
specific mAb against CD19 (clone SJ25-C1; Southern Bio-
technology Associates), with the Cy5-labeled mAb against
CD27 (clone 2E4; gift from RA van Lier, Academic Medical
Center, Amsterdam) and with fluorescein isothiocyanate
(FITC)-labeled mAb specific for one of the chemokine recep-
tors CXCR3 (clone 49801.111; R&D Systems), CXCR5
(clone 51505.111; R&D Systems), CCR5 (clone 45523.111;
R&D Systems), CCR6 (clone 53103.111; R&D Systems),
CCR7 (clone 3D12; a gift from M Lipp, Max Delbrück Center,
Berlin) or CCR9 (clone 112509.111; R&D Systems). Anti-
body against CXCR4 was labeled with phycoerythrin (PE;
clone 12G5; BD Pharmingen). Before incubation with strepta-
vidin-PE or streptavidin-FITC (for CXCR4) (0.5 µg/ml;
Pharmingen), cells were washed twice in phosphate-buffered
saline/2% BSA/4 mM EDTA.
To determine the frequency of CD5+ B cells, PBMC were
stained as described above with biotin-CD19, Cy5-CD27 and
PE-labeled mAb against CD5 (clone UCHT2; BD Pharmin-
gen). For the analysis of chemokine receptor expression,
CD5+ B cells were purified by magnetic cell sorting with
CD19-specific beads (Miltenyi). Isolated B cells were stained
as described above with PE-CD5 and Cy5-CD27 together
with the FITC-labeled mAb against the chemokine receptors
CXCR3 or CXCR5.
Propidium iodide (1 µg/ml; Sigma) was added immediately
before cytometric analysis for the exclusion of dead cells. Flow
cytometric analyses were performed by fluorescence-acti-
vated cell sorting (FACS) software (FACSCalibur and Cel-
lQuest; Becton Dickinson).
Measurement of CXCL10 concentrations
For further analysis, sera of controls and those of patients ana-
lyzed for chemokine receptor expression were stored at -20°C.
The concentration of CXCL10 was determined by using a sen-
sitive ELISA test kit (HyCult Biotechnology). Samples were
tested in duplicate and values were compared with a standard
curve.
Transmigration assay
Cell migration was examined in Transwell™ inserts (Corning
Costar) with a diameter of 6.5 mm and 5 µm pores, by using
fibronectin-precoated membranes as described previously
[24]. In brief, 5 × 105 PBMC were suspended in RPMI 1640
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R1003medium (Life Technologies) without methyl red, supplemented
with 0.5% BSA. Cells were added to the upper well and chem-
okine dilution or assay medium to the lower compartment; they
were incubated for 90 min at 37°C under CO2-buffered con-
ditions. Migrated cells from triplicate wells were pooled and
analyzed by flow cytometry. Optimal chemokine concentra-
tions for migration were 50 nM for CXCL12 (R&D Systems)
and 100 nM for CXCL10 (R&D Systems).
Statistical analyses
Statistical analyses were performed with GraphPad Prism
software (Prism 3.0 software for windows; GraphPad). Fre-
quencies of B cells were calculated with CellQuest software
(Becton Dickinson) and variations in chemokine receptor
expression on B cells within the analyzed group were com-
pared in a hierarchic statistic analysis, using Kruskal–Wallis
and the nonparametric Mann–Whitney U test. Correlations
were determined by Spearman's product-moment correlation
for interval data (GraphPad software). P < 0.05 was consid-
ered significant.
Results
Chemokine receptor expression on peripheral blood B 
cells of healthy controls
To analyze chemokine receptor expression on B cells of nor-
mal healthy volunteers PBMC were double-stained with anti-
bodies specific for the B cell marker CD19 and for the
chemokine receptors CXCR3, CXCR4, CXCR5, CCR5,
CCR6, CCR7 or CCR9. Data from a representative experi-
ment are depicted in Fig. 1. The cytometric analysis of healthy
controls showed that 93.9% of the B cells were positive for
CXCR3, 81.6% for CXCR4, 97.6% for CXCR5, 76.7% for
CCR6 and 94.3% for CCR7. Most B cells were negative for
the receptors CCR5 (only 5.6% positive) and CCR9 (only
1.7% positive).
Table 1
Demographics and medications of patients in the study
Parameter RA SLE OA Controls
Total numbers 26 11 13 21
Age (years)
Mean 55.1 42.5 71.2 42.6
Range 25–76 27–78 62–79 25–64
Sex (n)
Female 21 10 8 15
Male 5 1 5 6
Duration of disease (years)
Mean 8.1 9.5 3.3 -
Range 0.1–37 2–25 0.5–10 -
Clinical parameter (mean ± SD)
Leukocytes (109/l) 9.5 ± 2.7 4.3 ± 1.1 7.8 ± 2.7 nd
CRP (mg/dl) 3.1 ± 3.0 1.1 ± 0.9 0.5 ± 0.6 nd
ESR (mm/h) 37.5 ± 30.5 34.9 ± 16.7 28.5 ± 19.4 nd
Treatment (n)
None 6 - - 21
Corticosteroids and/or NSAID 7 - 8a -
Anti-TNF-α therapy 13b - - -
Predisolone - 11c - -
Cyclophosphamide (i.v.) - 6 - -
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; i.v., intravenous; nd, not determined; NSAID, non-steroidal anti-inflammatory drugs; 
OA, osteoarthritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus.
aTreatment with buprenorphine (1) or tramadol (1); btreatment with TNF-α-specific antibodies infliximab (6) or adalimumab (3) (mostly in 
combination with methotrexate) or with the soluble TNF-α receptor etanercept (2); ctreatment with predisolone alone (2), in combination with 
azathioprine (3), or in combination with cyclophosphamide (6).
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peripheral blood B cell subsets of patients with RA, with 
SLE and with OA
To assess changes in the pattern of B cell chemokine receptor
expression associated with RA (n = 26), SLE (n = 11) and OA
(n = 13) we compared the pattern in patients with that of a
group of healthy individuals (n = 21). In addition to mAb spe-
cific for CD19 and the respective chemokine receptors,
PBMC were stained with antibodies specific for CD27, which
allowed us to distinguish between naive B cells (CD27-),
memory B cells (CD27+) and plasma cells (CD27hi) [25]. Lev-
els of CD27 expression used to define the various B cell sub-
sets were defined by triple staining with CD19, CD20 and
CD27 as shown in Fig. 2a. The relative frequencies of B cells
are comparable in the control and in the different patient
groups, although the patients with RA did show a higher vari-
ation in the percentages of naive B cells, memory B cells and
plasma cells (Fig. 2b).
In healthy individuals most B cells (median value 93.8%, range
66.9 to 99.3%) were positive for CXCR5 (CXCR5+; Fig. 3).
Similar results were obtained with blood samples from
patients with OA. As shown in Fig. 3 the percentage of
CXCR5+ B cells was slightly higher (median 96.8%, range
90.6 to 99.6%, P = 0.05). In both of these groups, only a minor
fraction of B cells showed low expression of CXCR5. A repre-
sentative FACS analysis showing CXCR5 expression on
peripheral blood naive B cells, memory B cells and plasma
cells from a healthy control is shown in Fig. 7.
In contrast to the patients with OA, a decrease in the fraction
of CXCR5+ B cells was observed in most blood samples from
patients with RA and patients with SLE. In patients with RA the
median value for CXCR5+ B cells was decreased to 83.4% (P
= 0.01) and in patients with SLE to 81.8% (P = 0.02) (Fig. 3).
Whereas little variation in the frequency of CXCR5+ B cells
was seen in controls or in patients with OA, the expression of
CXCR5 on B cells varied enormously in patients with RA and
patients with SLE (Fig. 3). For patients with RA these values
ranged from 2.5 to 97.6% and for patients with SLE from 59.8
to 98.1% (Fig. 3).
The analysis of the different B cell subsets revealed that the
fraction of CXCR5+ cells decreases as B cells differentiate to
plasma cells. In healthy individuals the median value for the fre-
quency of CXCR5+ plasma cells was 70.6% (range 27.8 to
96.8%). In patients with RA and patients with SLE the expres-
sion of CXCR5 on peripheral blood plasma cells was reduced
to 39.3% (range 5.7 to 91.9%) and 45.6% (range 11.0 to
88.6%), respectively (Fig. 3). Overall, in patients with RA sig-
nificant differences in the fraction of CXCR5+ B cells were
found for naive B cells, memory B cells and plasma cells,
whereas in patients with SLE this was seen only for effector B
cells, memory B calls and plasma cells (Fig. 3).
Similar results were obtained when B cells were tested for the
chemokine receptor CXCR4. In both healthy controls and
patients with OA, most B cells expressed high levels of this
chemokine receptor, and little individual variation was seen
Figure 1
Expression of chemokine receptors in peripheral blood B cells from a healthy donor. Flow cytometric plots show chemokine receptor expression on 
CD19+ B cells. For each of the chemokine receptors tested the percentage of positive B cells is indicated. Isotype control (dotted line) is included.
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in healthy controls and patients with OA were 82.0% (range
68.4 to 89.3%) and 84.6% (range 74.7 to 91.5%), respec-
tively. In contrast, in patients with RA (n = 19) the percentage
of CXCR4+ B cells was lower and large individual variations
were found, from 7.3 to 89.4%. Similarly, in the few patients
with SLE who were tested (n = 4) a reduction in the percent-
age of CXCR4+ B cells was seen, ranging from 5.4 to 84.2%
(Fig. 4).
When B cells from patients with RA and patients with SLE
were tested for the expression of CCR6, again a reduction in
the frequency of CCR6+ B cells was observed. However, a
significant reduction in the frequency of CCR6+ B cells was
found only when B cells were analyzed from patients with RA
(P = 0.005; Fig. 5).
A great variation in chemokine receptor expression was
obtained when B cells were tested for CXCR3, which is a
receptor for chemokines that is upregulated in inflammation.
We found that in healthy individuals most B cells are positive
for CXCR3; however, the mean fluorescence intensity was
rather low and only a few B cells expressed CXCR3, at a level
comparable to that seen after staining with mAb specific for
CXCR5 (Figs 1 and 7). The analysis of blood samples from
patients with RA – and also from some patients with SLE –
revealed an increase in the fraction CXCR3-high-expressing
(CXCR3hi) B cells (Fig. 6). Again the percentage of CXCR3hi
B cells showed considerable variation between individual
patients. In RA the values ranged from 1.6 to 89.8% (Fig. 6).
The results obtained for CXCR3 suggest that its expression is
upregulated as B cells differentiate into memory B cells and
plasma cells. In most healthy controls the fraction of CXCR3hi
naive B cells was negligible. A comparable result was found
with blood samples from patients with OA and also with most
patients with SLE. In contrast, in patients with RA a significant
fraction of naive B cells showed high expression of CXCR3.
The frequency was further increased in memory B cells from
patients with RA (Figs 6 and 7). A comparison of B cells from
healthy individuals and from patients with RA showed that the
median value for naive B cells increased from 3.4% (range 0.4
to 15.7%) to 9.7% (range 2.8 to 43.1%) (P = 0.0006) and for
memory cells from 10.0% (range 5.4 to 28.3%) to 23.2%
(range 1.9 to 95.0%) (P = 0.003; Fig. 6). This highly signifi-
Figure 2
The frequency of B cells in healthy individuals and the different patient groups. (a) Triple staining with CD19, CD20 and CD27 was used to define 
naive B cells, memory B cells and plasma cells. Thresholds for CD27-, CD27+ and CD27hi are indicated. (b) Frequency for B cells and the different 
subpopulations. Data are given for healthy individuals (con) and for each of the patient groups analyzed: osteoarthritis (OA), rheumatoid arthritis (RA) 
and systemic lupus erythematosus (SLE). Box plots show the median values, 25th and 75th quartile and the range of values. Significant differences 
from controls are shown (*P < 0.05, **P < 0.005, ***P < 0.0005).
CD20
C
D
27
60,4%
38,4 %
1,2%
(a) (b)
naive B cells
memory B cells
plasma cells
(***) (**) (**)(**)
(**) (**) (*)
con OA RA SLE
0
25
50
75
100
0
25
50
75
100
0
25
50
75
100
0
25
50
75
100
ce
ll
fr
eq
ue
nc
y
[%
]
total B cells
plasma cells
naive B cells
memory B cells
con OA RA SLE
con OA RA SLE con OA RA SLE
Arthritis Research & Therapy    Vol 7 No 5    Henneken et al.
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observed when blood samples from patients with SLE were
analyzed.
Furthermore, we addressed the question of whether there is a
significant correlation between the expression of CXCR5 with
that of CXCR4, CCR6 and CXCR3. In patients with RA a
decreased fraction of CXCR5-expressing B cells correlated
with the expression of CCR6 (r = 0.53, P = 0.01; data not
shown). However, neither in patients with RA nor in patients
with SLE did we see a significant correlation in the expression
of CXCR5 and CXCR4. However, with regard to CXCR5 and
CXCR3 we found a negative correlation, but this was
restricted to patients with RA (r = -0.59, P = 0.007; Fig. 8).
Chemokine receptor expression on CD5+ B cells
Staining of PBMC of healthy controls showed that on average
20% of B cells were positive for CD5 (data not shown). Com-
parable frequencies of CD5 expression were found for
patients with RA (range 12 to 23% of B cells). To assess
chemokine receptor expression on CD5+ B cells, CD19+ B
cells were purified by magnetic cell sorting and stained for
CD5, CD27 and the respective chemokine receptor. Labeling
for CXCR5 showed that most CD5+ B cells were positive for
CXCR5 and only a fraction of CD5+ plasma cells was negative
for CXCR5 (data not shown). The frequency of CXCR3hi B
cells was the same for the CD5+ and CD5- B cell populations.
There was therefore no evidence that CXCR3 expression is
preferentially enhanced on CD5+ B cells.
Figure 3
Chemokine receptor CXCR5+ expression on B cell subpopulations. The percentage of total B cells, naive B cells, memory B cells and plasma cells 
expressing CXCR5+ are given. Box plots show the median values, 25th and 75th quartile and the range of values. Significant differences from con-
trols are shown (*P < 0.05, **P < 0.005).
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PBMC were isolated by Ficoll gradient centrifugation. In the
supernatant the concentration of CXCL10 was measured with
a standard ELISA test. In both sera from the different patient
groups and from healthy controls only low levels of CXCL10
were detectable (about 200 pg/ml; Fig. 9). Only a single
patient with SLE showed slightly increased levels of CXCL10.
Influence of medication on chemokine receptor 
expression
To determine a potential influence of medication, five blood
samples of newly diagnosed patients with RA were analyzed
before treatment. In three of the samples, B cells showed a
pattern of chemokine receptor expression as described above,
in that the median value for the frequency of B cells with high
levels of CXCR5 was decreased from 93.8% (range 66.9 to
99.3%) to 79.4% (range 2.6 to 96.8%) (Fig. 10). Variations in
chemokine receptor expression were also seen in patients (n
= 10) under treatment with tumor necrosis factor (TNF) block-
ers (infliximab, etanercept and adalimumab). However, this
was not found in patients with RA (n = 4) under treatment with
corticoids and/or non-steroidal anti-inflammatory drugs
(NSAID). In these patients practically all B cells were CXCR5+
(median 95.5%, range 88.1 to 97.8%; Fig. 10).
The analysis of CXCR3 expression on B cells revealed that in
comparison with healthy individuals, untreated patients with
RA had an increase in the frequency of CXCR3hi B cells. Most
strikingly, an increase in the percentage of CXCR3hi naive B
cells, a finding characteristic for patients with RA, was
observed. This increase was seen also under anti-TNF-α
therapy and to some extent when patients where treated with
corticoids and/or NSAID. The observed modulation of chem-
okine receptor expression on peripheral blood B cells from
patients with RA therefore does not simply reflect the disease
activity and/or the influence of therapy.
Figure 4
Chemokine receptor CXCR4+ expression on B cell subpopulations. The percentage of total B cells, naive B cells, memory B cells and plasma cells 
expressing CXCR4+ are given. Box plots show the median values, 25th and 75th quartile and the range of values. Significant differences from con-
trols are shown (*P < 0.05).
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cell migration
To test whether low expression of CXCR3 on B cells is suffi-
cient to respond to the inflammatory chemokine CXCL10,
PBMC from patients with RA were tested with the use of a
transmigration assay (Fig. 11). A cytometric analysis of the
migrated cells revealed that both fractions of memory B cells,
CXCR3hi and CXCR3lo B cells, migrated toward CXCL10
(Fig. 11). In contrast, in an analysis of migration towards the
chemokine CXCL12, only CXCR4+ B cells responded;
CXCR4- B cells did not (Fig. 11). The in vitro chemotaxis assay
suggested that CXCR3-low-expressing B cells are function-
ally reactive towards the chemokine CXCL10.
Discussion
The analysis of peripheral blood B cells from patients with RA
and patients with SLE showed significant differences in their
chemokine receptor expression when compared with B cells
from healthy individuals and also from patients with OA. In
patients with RA and patients with SLE a fraction of B cells
showed decreased expression of CXCR5, CXCR4 and
CCR6, chemokine receptors that have been associated with
B cell homing into follicles [26,27]. In contrast, the expression
of CXCR3, a receptor reactive to inflammatory chemokines
[4,10], was increased. These changes in chemokine receptor
expression seem to be associated with chronic inflammation,
because they were not observed when B cells from patients
with OA were analyzed. Importantly, a comparison of B cells
from patients with RA and patients with SLE showed distinct
disease signatures. A negative correlation of CXCR5 and
CXCR3 expression in B cells was seen only in patients with
RA.
CXCR5 was previously shown to be expressed on most
mature circulating B cells [8]. This receptor is the main chem-
okine receptor responsible for the controlled migration of B
Figure 5
Chemokine receptor CCR6+ expression on B cell subpopulations. The percentage of total B cells, naive B cells, memory B cells and plasma cells 
expressing CCR6+ are given. Box plots show the median values, 25th and 75th quartile and the range of values. Significant differences from controls 
are shown (**P < 0.005).
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R1009cells into secondary lymphoid organs [28]. The analysis of
blood samples from healthy individuals showed that after acti-
vation of B cells and their differentiation into plasma cells and
to some extent into memory cells, CXCR5 becomes downreg-
ulated (Fig. 3). In line with these results are data from an exper-
iment in vitro in which stimulation with anti-CD40 antibodies
led to a downregulation of CXCR5 [29]. The finding of a sig-
nificant decrease in the fraction of CXCR5+ B cells in patients
with RA and also in patients with SLE by our study may reflect
the chronic activation of B cells as reported for these groups
of patients [30].
Lower levels of chemokine receptor CXCR5 and higher levels
of CXCR3 on peripheral blood B cells may represent a gener-
alized change in the profile and might be seen on all of the
activated B cells in the systemic compartment or these
changes in chemokine receptor expression might serve in
selective recruitment into the inflamed tissue. In line with this
interpretation we observed CXCR3 expression on synovial tis-
sue B cells. However, comprehensive studies are under way
to further delineate the expression of chemokine receptors and
their function in migration into the effected tissue.
CXCR3 was described as a marker for malignant B cells, and
its expression on normal peripheral blood B cells has been
controversial [20,21]. Our results show that practically all B
cells express CXCR3, although with a low mean fluorescence
intensity. After differentiation, the level of CXCR3 expression
seems to be upregulated because the frequency of CXCR3hi
B cells increases from naive to memory B cells. Activation of
human B cells using a culture system in vitro showed that after
stimulation with cytokines the expression of CXCR3 is
Figure 6
Chemokine receptor CXCR3hi expression on B cell subpopulations. The percentage of total B cells, naive B cells, memory B cells and plasma cells 
expressing CXCR3hi are given. Box plots show the median values, 25th and 75th quartile and the range of values. Significant differences from con-
trols are shown (**P < 0.005, ***P < 0.0005).
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that after activation with interleukin-2 the expression of
CXCR3 is upregulated [32]. The observed increase in the fre-
quency of CXCR3hi B cells may result from the chronic activa-
tion and differentiation of B cells in patients with RA.
A significant increase in the fraction of CXCR3hi B cells was
observed only when blood samples from patients with RA
were analyzed (Fig. 6). In sera of patients with SLE but not in
those from patients with RA, Narumi and colleagues [33]
described high titers of CXCL10. Because CXCR3 expres-
sion may be influenced by the level of CXCL10, sera from
healthy controls and from the different patient groups were
tested for the presence of this chemokine. However, we did
not find elevated titers of CXCL10 in our patients with SLE
(Fig. 9). These results exclude the possibility that a ligand-
induced receptor internalization might underlie the lower fre-
quency of CXCR3hi-expressing B cells in patients with SLE.
Using a transmigration assay we were able to show that low
levels of CXCR3 expression are sufficient to permit a
response to the migrational stimulus of the chemokine
CXCL10. However, these chemotaxis results in vitro are not
necessarily predictive of their lymphocyte-recruiting activity in
vivo. The different levels of chemokine receptor CXCR3 on
peripheral blood B cells may still affect B cell migration. Ele-
vated levels of the interferon-γ-inducible chemokines CXCL9
and CXCL10, both ligands for CXCR3, have been found in
chronically inflamed synovial tissue [10]. These chemokines,
which are normally involved in the chemotaxis of neutrophils, T
cells and mast cells, might also influence the migration of
CXCR3+ B cells. Further experiments will be required to show
whether the significant upregulation of CXCR3 on peripheral
Figure 7
Modulation of CXCR3 and CXCR5 expression in patients. A represent-
ative fluorescence-activated cell sorting analysis for chemokine recep-
tor expression on peripheral B cells (CD19+) is shown. The 
percentages of CXCR5+ and CXCR3hi B cells are given for healthy 
controls (con) and patients with osteoarthritis (OA), rheumatoid arthritis 
(RA) and systemic lupus erythematosus (SLE).
Figure 8
Negative correlation in the frequency of CXCR3hi and CXCR5+ B cells in patients with RA
in patients with RA. Correlation factor (Spearman's) and P value are 
indicated (GraphPad software).
Figure 9
CXCL10 concentrations in sera. Sera of healthy controls and of 
patients with rheumatoid arthritis, systemic lupus erythematosus and 
osteoarthritis were tested in a standard ELISA test. A D450 of 0.06 cor-
responds to 200 pg/ml CXCL10 (concentration after Ficoll centrifuga-
tion); for each of the groups analyzed median values are indicated. Con, 
control; OA, osteoarthritis; RA, rheumatoid arthritis; SLE, systemic 
lupus erythematosus.
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R1011blood B cells supports their accumulation in the inflamed syn-
ovial tissue.
Whereas B cells from healthy controls and patients with OA
showed little inter-individual variation in the expression of
chemokine receptors, individual patients with RA and patients
with SLE gave a rather heterogeneous picture (Fig. 7). For
each of the chemokine receptors analyzed, the fractions of
negative, low and highly positive B cells varied tremendously
and were seen on both B cells and memory cells.
Little is known about the mechanisms controlling chemokine
receptor expression and what might cause the variability in
their expression level on peripheral blood B cells. One possi-
bility might be that the modulation of chemokine receptor
expression is associated with rheumatoid factor (RF) antibody
titers. The majority of patients with RA analyzed were positive
for RF. A correlation of chemokine receptor expression and the
level of RF was therefore not seen.
An attempt to correlate the level of chemokine receptor
expression with age or sex of the patients, with disease dura-
tion or with disease activity failed. There was no clear-cut
correlation to be seen. Furthermore, from our data it seems
unlikely that the variability in chemokine receptor expression
results from the different treatment regimes of individual
patients with RA (Fig. 10). Individual variability of chemokine
receptor expression on B cells was as great in recently
diagnosed, yet untreated, patients with RA as in those receiv-
ing anti-TNF-α therapies, which suggests that TNF-α itself is
unlikely to be the cause of receptor modulation.
RA and SLE are chronic inflammatory diseases, and both are
characterized by a continuous activation of B cells. Whereas
Figure 10
Effect of treatment on CXCR3 and CXCR5 expression. Data are shown for healthy individuals, untreated patients with rheumatoid arthritis and 
patients treated with corticoid and/or non-steroidal anti-inflammatory drugs or treatment with anti-tumor necrosis factor-α therapy. The percentage of 
CXCR3hi and CXCR5+ B cells is shown for total B cells and the subpopulation of naive B cells. Box plots show the median values, 25th and 75th 
quartile and the range of values. Significant differences from controls are shown (*P < 0.05, **P < 0.005). Con, control; RA, rheumatoid arthritis; 
SLE, systemic lupus erythematosus.
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R1012SLE is a more systemic inflammatory disease, in most patients
with RA the inflammation is localized primarily to the synovial
membrane. To what extent the described differences in chem-
okine receptor expression between B cells from patients with
RA and patients with SLE might influence the migrational pat-
tern of B cells needs to be delineated by continuing studies,
potentially permitting new therapeutic avenues.
Conclusion
Here we show that chronic inflammation influences chemokine
receptor expression on peripheral blood B cells. Receptors for
homeostatic chemokines, like CXCL13 and CXCL12 showed
reduced levels of expression whereas CXCR3 a receptor for
inflammatory chemokines becomes unregulated. Differences
between RA and SLE patients suggest a disease specific reg-
ulation of chemokine receptor expression, which may influence
the migrational behavior of B cells.
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